Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sherry Evans

Nurse Practitioner Cincinnati, OH Nurse Practitioner

NPI 1659411064 CMS profile 10776988

8444 Winton Road, Cincinnati, OH 45231

Open in the dashboard

General payments

$8,678

344 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sherry Evans of Cincinnati, OH is reported in the CMS Open Payments database as having received $8,678 across 344 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,444 57
2024 General $1,800 77
2023 General $2,712 93
2022 General $1,449 63
2021 General $1,272 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sherry Evans
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Sherry Evans were reported at $1,444. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Sherry Evans Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,272 $135 $40–$426 $132
2022 $1,449 $152 $48–$470 $149
2023 $2,712 $166 $54–$529 $160
2024 $1,800 $173 $55–$556 $164
2025 $1,444 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $2,365 53 payments
  2. CSL Behring $1,309 56 payments
  3. Amgen Inc. $926 29 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $744 37 payments
  5. Blueprint Medicines Corporation $540 25 payments
  6. Regeneron Healthcare Solutions, Inc. $316 15 payments
  7. Grifols USA, LLC $270 13 payments
  8. ALK-Abello, Inc $217 10 payments
  9. Novartis Pharmaceuticals Corporation $215 11 payments
  10. GlaxoSmithKline, LLC. $213 11 payments
  11. Other $1,563 84 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,674 340 payments
  2. Education $4 4 payments
Products named General payments · program years 2021–2025
  1. TEZSPIRE Respiratory $1,666 19 payments
  2. TEZSPIRE Inflammation $799 26 payments
  3. Haegarda $708 26 payments
  4. Hizentra $565 28 payments
  5. TAKHZYRO $472 23 payments
  6. FASENRA $443 21 payments
  7. AYVAKIT $406 20 payments
  8. Prolastin-C Liquid $226 11 payments
  9. Grastek $217 10 payments
  10. Ragwitek $217 10 payments
  11. Other $3,588 181 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

344 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record